The long term goal of the proposed research is to purify the enzymes which phosphorylate phosphatidylinositol (PI) and characterize their structure, mechanism of action and regulation. Recent results from several laboratories have implicated these enzymes as being important in mediation of hormone responses. The inositol-1,4,5-trisphosphate (IP3) which regulates free Ca2+ levels in the cytoplasm is derived from hydrolysis of phosphotidylinositol-4,5-bisphosphate (PIP2). In addition, since much of the cellular diacylglycerol (DG) derives from breakdown of PI, and since free Ca2+ levels appear to affect this breakdown, it seems likely that PIP2 breakdown is both directly and indirectly affecting the diacylglycerol level in cells. Thus, PIP2 is a critical intermediate in the pathway for production of two important second messengers. These second messengers have been proposed as mediators of a variety of hormone actions including proliferative responses to certain growth factors. We have proposed that an increase in the rate of phosphorylation of PI to phosphatidylinositol-4-phosphate (PIP) and to phosphatidylinositol-4,5-bisphosphate (PIP2) could enhance responses to hormones by providing additional substrate for production of the second messengers. We now wish to purify these enzymes to homogeneity and characterize their structure, substrate specificity, and mechanism of regulation.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM036624-01
Application #
3290974
Study Section
Physical Biochemistry Study Section (PB)
Project Start
1986-07-01
Project End
1991-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Wong, Kwok-Kin; Engelman, Jeffrey A; Cantley, Lewis C (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20:87-90
Myers, Andrea P; Meyerhardt, Jeffrey A; Cantley, Lewis C (2009) Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? Clin Cancer Res 15:6748-50
Engelman, Jeffrey A; Chen, Liang; Tan, Xiaohong et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-6
Chang, James D; Field, Seth J; Rameh, Lucia E et al. (2004) Identification and characterization of a phosphoinositide phosphate kinase homolog. J Biol Chem 279:11672-9
Nishikawa, K; Toker, A; Wong, K et al. (1998) Association of protein kinase Cmu with type II phosphatidylinositol 4-kinase and type I phosphatidylinositol-4-phosphate 5-kinase. J Biol Chem 273:23126-33
Yoakim, M; Hou, W; Songyang, Z et al. (1994) Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity. Mol Cell Biol 14:5929-38
Liscovitch, M; Chalifa, V; Pertile, P et al. (1994) Novel function of phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D. J Biol Chem 269:21403-6
Wong, K; Cantley, L C (1994) Cloning and characterization of a human phosphatidylinositol 4-kinase. J Biol Chem 269:28878-84
Kapeller, R; Prasad, K V; Janssen, O et al. (1994) Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem 269:1927-33
Prasad, K V; Janssen, O; Kapeller, R et al. (1993) Src-homology 3 domain of protein kinase p59fyn mediates binding to phosphatidylinositol 3-kinase in T cells. Proc Natl Acad Sci U S A 90:7366-70

Showing the most recent 10 out of 38 publications